185 related articles for article (PubMed ID: 36609489)
1. Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications.
Sznol M; Rizvi N
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609489
[TBL] [Abstract][Full Text] [Related]
2. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Buchbinder EI; Dutcher JP; Daniels GA; Curti BD; Patel SP; Holtan SG; Miletello GP; Fishman MN; Gonzalez R; Clark JI; Richart JM; Lao CD; Tykodi SS; Silk AW; McDermott DF
J Immunother Cancer; 2019 Feb; 7(1):49. PubMed ID: 30777131
[TBL] [Abstract][Full Text] [Related]
3. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 2 in cancer therapy.
Antony GK; Dudek AZ
Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
[TBL] [Abstract][Full Text] [Related]
6. Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report.
Anastasopoulou A; Gkoufa A; Diamantopoulos P; Kazanas S; Eliadi I; Samarkos M; Gogas H
Immunotherapy; 2022 Sep; 14(13):1015-1020. PubMed ID: 35852114
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 therapy of cancer-clinical perspectives.
Majidpoor J; Mortezaee K
Int Immunopharmacol; 2021 Sep; 98():107836. PubMed ID: 34218217
[TBL] [Abstract][Full Text] [Related]
8. Clinical applications of IL-2.
Sznol M; Parkinson DR
Oncology (Williston Park); 1994 Jun; 8(6):61-7; discussion 67, 71, 74-5. PubMed ID: 7521197
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
10. The IL-2 cytokine family in cancer immunotherapy.
Sim GC; Radvanyi L
Cytokine Growth Factor Rev; 2014 Aug; 25(4):377-90. PubMed ID: 25200249
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
Ridolfi L; de Rosa F; Ridolfi R; Gentili G; Valmorri L; Scarpi E; Parisi E; Romeo A; Guidoboni M
J Transl Med; 2014 Sep; 12():262. PubMed ID: 25245327
[TBL] [Abstract][Full Text] [Related]
12. The role of interleukin-2 in the biotherapy of cancer.
Parkinson DR
Oncol Nurs Forum; 1989; 16(6 Suppl):16-20. PubMed ID: 2687810
[TBL] [Abstract][Full Text] [Related]
13. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
14. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
15. Cytokines in the Treatment of Melanoma.
Bentebibel SE; Diab A
Curr Oncol Rep; 2021 May; 23(7):83. PubMed ID: 34003395
[TBL] [Abstract][Full Text] [Related]
16. In vitro predictors of clinical response in patients receiving interleukin-2-based immunotherapy.
Schwartzentruber DJ
Curr Opin Oncol; 1993 Nov; 5(6):1055-8. PubMed ID: 8305539
[TBL] [Abstract][Full Text] [Related]
17. High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?
Amin A; White RL
Oncology (Williston Park); 2013 Jul; 27(7):680-91. PubMed ID: 23977763
[TBL] [Abstract][Full Text] [Related]
18. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for metastatic renal cell carcinoma.
Wirth MP
Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2: clinical applications.
Atkins MB
Semin Oncol; 2002 Jun; 29(3 Suppl 7):12-7. PubMed ID: 12068383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
